Expression of Intragenic LCAL4 Long Non-Coding RNAs as a Potential Diagnostic and Prognostic Marker in Female Breast Cancer
,
Abstract
Objective: In breast cancer early detection is associated with reduced mortality and it is essential to identify new biomarkers for early detection and appropriate management of cancer patients with the best response to treatment. Long non-coding RNAs (LncRNAs) have attracted much attention as potential diagnostic, prognostic, or predictive biomarkers due to their high specificity, easy access to non-invasive methods, and their aberrant expression under various pathological and physiological conditions. Have attracted the aim of this study is to investigate the expression profile of intragenic
non-coding LncRNAs LCAL4 as a biomarker as potential diagnostic and prognostic biomarkers in cancer.
Materials and methods: In this research, 62 tissue samples were obtained from patients undergoing therapeutic surgery in Khatam al-Anbia Hospital and the normal peripheral tissue that was removed for prevention was used as a control by Real-time PCR method.
Results: The expression pattern of LCAL4 long non-coding RNA gene is significantly different between two groups of healthy control samples and samples obtained from patients with different breast cancer subtypes, Also its expression between samples obtained from different subgroups and different stages showed significant differences.
Conclusion: The studied LncRNAs can act as a factor to identify tumor tissue from healthy tissue, and the diagnosis of cancer grades can be different depending on the type of LncRNA. These results can be proposed in the introduction of LncRNA LCAL4 as a new marker in the diagnosis of breast cancer. In addition, by interpreting the results, it can be concluded that these LncRNAs can be considered as influential factors in the process of breast cancer.
1. Momenimovahed Z, Salehiniya H. Epidemiological characteristics of and risk factors for breast cancer in the world. Breast Cancer (Dove Med Press). 2019 Apr 10;11:151-164.
2. Martin AM, Weber BL. Genetic and hormonal risk factors in breast cancer. J Natl Cancer Inst. 2000 Jul 19;92(14):1126-35.
3. Feldheim W, Metzner C. Nutritional factors and breast cancer. Ernahrungs-Umschau. 1999;46(2):60-.61.
4. Charishma GCG, Kusuma PNKPN, Narendra JBNJB. Review on breast cancer and its treatment. International Journal of Indigenous Herbs and Drugs. 2020; 5(3): 21-26
5. Sakorafas GH, Blanchard K, Sarr MG, Farley DR. Paget's disease of the breast. Cancer Treat Rev. 2001 Feb;27(1):9-18.
6. Baek AE, Nelson ER. The Contribution of Cholesterol and Its Metabolites to the Pathophysiology of Breast Cancer. Horm Cancer. 2016 Aug;7(4):219-28.
7. Early Breast Cancer Trialists' Collaborative Group. Effects of radiotherapy and surgery in early breast cancer. An overview of the randomized trials. N Engl
J Med. 1995 Nov 30;333(22):1444-55.
8. Lü L, Sun J, Shi P, Kong W, Xu K, He B, Zhang S, Wang J. Identification of circular RNAs as a promising new class of diagnostic biomarkers for human breast cancer. Oncotarget. 2017 Jul 4;8(27):44096-44107.
9. Tseng YY, Moriarity BS, Gong W, Akiyama R, Tiwari A, Kawakami H, et al. PVT1 dependence in cancer with MYC copy-number increase. Nature. 2014;512(7512):82-6.
10. Hombach S, Kretz M. Non-coding RNAs: Classification, Biology and Functioning. Adv Exp Med Biol. 2016;937:3-17.
11. Hajarnis S, Lakhia R, Patel V. MicroRNAs and Polycystic Kidney Disease. In: Li X, editor. Polycystic Kidney Disease [Internet]. Brisbane (AU): Codon Publications; 2015. Chapter 13. Available from: https://www.ncbi.nlm.nih.gov/books/NBK373371/
12. Bader AG, Brown D, Stoudemire J, Lammers P. Developing therapeutic microRNAs for cancer. Gene Ther. 2011;18(12):1121-6.
13. Cho WC. MicroRNAs in cancer - from research to therapy. Biochim Biophys Acta. 2010;1805(2):209-17.
14. Bridges MC, Daulagala AC, Kourtidis A. LNCcation: lncRNA localization and function. J Cell Biol. 2021;220(2):e202009045.
15. Zhu J, Fu H, Wu Y, Zheng X. Function of lncRNAs and approaches to lncRNA-protein interactions. Sci China Life Sci. 2013;56(10):876-85.
16. Volders PJ, Helsens K, Wang X, Menten B, Martens L, Gevaert K, et al. LNCipedia: a database for annotated human lncRNA transcript sequences and structures. Nucleic Acids Res. 2013;41 (Database issue):D246-51.
17. Chen LL. Towards higher-resolution and in vivo understanding of lncRNA biogenesis and function. Nat Methods. 2022;19(10):1152-1155.
18. Beermann J, Piccoli MT, Viereck J, Thum T. Non-coding RNAs in Development and Disease: Background, Mechanisms, and Therapeutic Approaches. Physiol Rev. 2016;96(4):1297-325.
19. Collins L, Binder P, Chen H, Wang X. Regulation of Long Non-coding RNAs and MicroRNAs in Heart Disease: Insight Into Mechanisms and Therapeutic Approaches. Front Physiol. 2020;11:798.
20. Wang Y, Song B, Zhu L, Zhang X. Long non-coding RNA, LINC01614 as a potential biomarker for prognostic prediction in breast cancer. PeerJ. 2019;7:e7976.
21. Fattahi S, Kosari‐Monfared M, Golpour M, Emami Z, Ghasemiyan M, Nouri M, et al. LncRNAs as potential diagnostic and prognostic biomarkers in gastric cancer: a novel approach to personalized medicine. Journal of Cellular Physiology. 2020;235(4):3189-206.
22. Lu C, Li Z, Hu S, Cai Y, Peng K. LncRNA PART-1 targets TGFBR2/Smad3 to regulate cell viability and apoptosis of chondrocytes via acting as miR-590-3p sponge in osteoarthritis. J Cell Mol Med. 2019;23(12):8196-8205.
23. Charles Richard JL, Eichhorn PJA. Platforms for Investigating LncRNA Functions. SLAS Technol. 2018;23(6):493-506.
24. Xue M, Chen W, Li X. Urothelial cancer associated 1: a long noncoding RNA with a crucial role in cancer.
J Cancer Res Clin Oncol. 2016;142(7):1407-19.
25. Liz J, Esteller M. lncRNAs and microRNAs with a role in cancer development. Biochim Biophys Acta. 2016;1859(1):169-76.
26. Federhen S. The NCBI Taxonomy database. Nucleic Acids Res. 2012;40(Database issue):D136-43.
27. Barrett T, Wilhite SE, Ledoux P, Evangelista C, Kim IF, Tomashevsky M, et al. NCBI GEO: archive for functional genomics data sets--update. Nucleic Acids Res. 2013 Jan;41(Database issue):D991-5.
28. Peng F, Wang R, Zhang Y, Zhao Z, Zhou W, Chang Z, et al. Differential expression analysis at the individual level reveals a lncRNA prognostic signature for lung adenocarcinoma. Mol Cancer. 2017;16(1):98.
29. Johnston SR. New strategies in estrogen receptor-positive breast cancer. Clin Cancer Res. 2010;16(7):1979-87.
30. Cai Q, Zhao X, Wang Y, Li S, Wang J, Xin Z, et al. LINC01614 promotes osteosarcoma progression via miR-520a-3p/SNX3 axis. Cell Signal. 2021;83:109985.
31. Yuan H, Yan L, Wu M, Shang Y, Guo Q, Ma X, et al. Analysis of the Estrogen Receptor-Associated LncRNA Landscape Identifies a Role for ERLC1 in Breast Cancer Progression. Cancer Res. 2022;82(3):391-405.
32. Zhao E, Lan Y, Quan F, Zhu X, A S, Wan L, et al. Identification of a Six-lncRNA Signature With Prognostic Value for Breast Cancer Patients. Front Genet. 2020;11:673.
33. Wu H, Zhou J, Chen S, Zhu L, Jiang M, Liu A. Survival-Related lncRNA Landscape Analysis Identifies LINC01614 as an Oncogenic lncRNA in Gastric Cancer. Front Genet. 2021;12:698947.
34. Wang H, Wu J, Guo W. SP1-Mediated Upregulation of lncRNA LINC01614 Functions a ceRNA for miR-383 to Facilitate Glioma Progression Through Regulation of ADAM12. Onco Targets Ther. 2020;13:4305-4318.
35. Yan S, Xu J, Liu B, Ma L, Tan H, Fang C. Integrative bioinformatics analysis identifies LINC01614 as a potential prognostic signature in esophageal cancer.
Transl Cancer Res. 2021;10(4):1804-1812.
36. Liu T, Han C, Fang P, Ma Z, Wang X, Chen H, et al. Cancer-associated fibroblast-specific lncRNA LINC01614 enhances glutamine uptake in lung adenocarcinoma. J Hematol Oncol. 2022;15(1):141.
37. Sun Y, Ling C. Analysis of the long non-coding RNA LINC01614 in non-small cell lung cancer. Medicine (Baltimore). 2019;98(30):e16437.
38. Hou Y, Zhou M, Li Y, Tian T, Sun X, Chen M, et al. Risk SNP-mediated LINC01614 upregulation drives head and neck squamous cell carcinoma progression via PI3K/AKT signaling pathway. Mol Carcinog. 2022;61(8):797-811.
39. Chen LJ, Wu L, Wang W, Zhai LL, Xiang F, Li WB,
et al. Long non‑coding RNA 01614 hyperactivates WNT/β‑catenin signaling to promote pancreatic cancer progression by suppressing GSK‑3β. Int J Oncol. 2022;61(4):116.
40. Li L, Wei H, Zhang YW, Zhao S, Che G, Wang Y, et al. Differential expression of long non-coding RNAs as diagnostic markers for lung cancer and other malignant tumors. Aging (Albany NY). 2021;13(20):23842-23867.
2. Martin AM, Weber BL. Genetic and hormonal risk factors in breast cancer. J Natl Cancer Inst. 2000 Jul 19;92(14):1126-35.
3. Feldheim W, Metzner C. Nutritional factors and breast cancer. Ernahrungs-Umschau. 1999;46(2):60-.61.
4. Charishma GCG, Kusuma PNKPN, Narendra JBNJB. Review on breast cancer and its treatment. International Journal of Indigenous Herbs and Drugs. 2020; 5(3): 21-26
5. Sakorafas GH, Blanchard K, Sarr MG, Farley DR. Paget's disease of the breast. Cancer Treat Rev. 2001 Feb;27(1):9-18.
6. Baek AE, Nelson ER. The Contribution of Cholesterol and Its Metabolites to the Pathophysiology of Breast Cancer. Horm Cancer. 2016 Aug;7(4):219-28.
7. Early Breast Cancer Trialists' Collaborative Group. Effects of radiotherapy and surgery in early breast cancer. An overview of the randomized trials. N Engl
J Med. 1995 Nov 30;333(22):1444-55.
8. Lü L, Sun J, Shi P, Kong W, Xu K, He B, Zhang S, Wang J. Identification of circular RNAs as a promising new class of diagnostic biomarkers for human breast cancer. Oncotarget. 2017 Jul 4;8(27):44096-44107.
9. Tseng YY, Moriarity BS, Gong W, Akiyama R, Tiwari A, Kawakami H, et al. PVT1 dependence in cancer with MYC copy-number increase. Nature. 2014;512(7512):82-6.
10. Hombach S, Kretz M. Non-coding RNAs: Classification, Biology and Functioning. Adv Exp Med Biol. 2016;937:3-17.
11. Hajarnis S, Lakhia R, Patel V. MicroRNAs and Polycystic Kidney Disease. In: Li X, editor. Polycystic Kidney Disease [Internet]. Brisbane (AU): Codon Publications; 2015. Chapter 13. Available from: https://www.ncbi.nlm.nih.gov/books/NBK373371/
12. Bader AG, Brown D, Stoudemire J, Lammers P. Developing therapeutic microRNAs for cancer. Gene Ther. 2011;18(12):1121-6.
13. Cho WC. MicroRNAs in cancer - from research to therapy. Biochim Biophys Acta. 2010;1805(2):209-17.
14. Bridges MC, Daulagala AC, Kourtidis A. LNCcation: lncRNA localization and function. J Cell Biol. 2021;220(2):e202009045.
15. Zhu J, Fu H, Wu Y, Zheng X. Function of lncRNAs and approaches to lncRNA-protein interactions. Sci China Life Sci. 2013;56(10):876-85.
16. Volders PJ, Helsens K, Wang X, Menten B, Martens L, Gevaert K, et al. LNCipedia: a database for annotated human lncRNA transcript sequences and structures. Nucleic Acids Res. 2013;41 (Database issue):D246-51.
17. Chen LL. Towards higher-resolution and in vivo understanding of lncRNA biogenesis and function. Nat Methods. 2022;19(10):1152-1155.
18. Beermann J, Piccoli MT, Viereck J, Thum T. Non-coding RNAs in Development and Disease: Background, Mechanisms, and Therapeutic Approaches. Physiol Rev. 2016;96(4):1297-325.
19. Collins L, Binder P, Chen H, Wang X. Regulation of Long Non-coding RNAs and MicroRNAs in Heart Disease: Insight Into Mechanisms and Therapeutic Approaches. Front Physiol. 2020;11:798.
20. Wang Y, Song B, Zhu L, Zhang X. Long non-coding RNA, LINC01614 as a potential biomarker for prognostic prediction in breast cancer. PeerJ. 2019;7:e7976.
21. Fattahi S, Kosari‐Monfared M, Golpour M, Emami Z, Ghasemiyan M, Nouri M, et al. LncRNAs as potential diagnostic and prognostic biomarkers in gastric cancer: a novel approach to personalized medicine. Journal of Cellular Physiology. 2020;235(4):3189-206.
22. Lu C, Li Z, Hu S, Cai Y, Peng K. LncRNA PART-1 targets TGFBR2/Smad3 to regulate cell viability and apoptosis of chondrocytes via acting as miR-590-3p sponge in osteoarthritis. J Cell Mol Med. 2019;23(12):8196-8205.
23. Charles Richard JL, Eichhorn PJA. Platforms for Investigating LncRNA Functions. SLAS Technol. 2018;23(6):493-506.
24. Xue M, Chen W, Li X. Urothelial cancer associated 1: a long noncoding RNA with a crucial role in cancer.
J Cancer Res Clin Oncol. 2016;142(7):1407-19.
25. Liz J, Esteller M. lncRNAs and microRNAs with a role in cancer development. Biochim Biophys Acta. 2016;1859(1):169-76.
26. Federhen S. The NCBI Taxonomy database. Nucleic Acids Res. 2012;40(Database issue):D136-43.
27. Barrett T, Wilhite SE, Ledoux P, Evangelista C, Kim IF, Tomashevsky M, et al. NCBI GEO: archive for functional genomics data sets--update. Nucleic Acids Res. 2013 Jan;41(Database issue):D991-5.
28. Peng F, Wang R, Zhang Y, Zhao Z, Zhou W, Chang Z, et al. Differential expression analysis at the individual level reveals a lncRNA prognostic signature for lung adenocarcinoma. Mol Cancer. 2017;16(1):98.
29. Johnston SR. New strategies in estrogen receptor-positive breast cancer. Clin Cancer Res. 2010;16(7):1979-87.
30. Cai Q, Zhao X, Wang Y, Li S, Wang J, Xin Z, et al. LINC01614 promotes osteosarcoma progression via miR-520a-3p/SNX3 axis. Cell Signal. 2021;83:109985.
31. Yuan H, Yan L, Wu M, Shang Y, Guo Q, Ma X, et al. Analysis of the Estrogen Receptor-Associated LncRNA Landscape Identifies a Role for ERLC1 in Breast Cancer Progression. Cancer Res. 2022;82(3):391-405.
32. Zhao E, Lan Y, Quan F, Zhu X, A S, Wan L, et al. Identification of a Six-lncRNA Signature With Prognostic Value for Breast Cancer Patients. Front Genet. 2020;11:673.
33. Wu H, Zhou J, Chen S, Zhu L, Jiang M, Liu A. Survival-Related lncRNA Landscape Analysis Identifies LINC01614 as an Oncogenic lncRNA in Gastric Cancer. Front Genet. 2021;12:698947.
34. Wang H, Wu J, Guo W. SP1-Mediated Upregulation of lncRNA LINC01614 Functions a ceRNA for miR-383 to Facilitate Glioma Progression Through Regulation of ADAM12. Onco Targets Ther. 2020;13:4305-4318.
35. Yan S, Xu J, Liu B, Ma L, Tan H, Fang C. Integrative bioinformatics analysis identifies LINC01614 as a potential prognostic signature in esophageal cancer.
Transl Cancer Res. 2021;10(4):1804-1812.
36. Liu T, Han C, Fang P, Ma Z, Wang X, Chen H, et al. Cancer-associated fibroblast-specific lncRNA LINC01614 enhances glutamine uptake in lung adenocarcinoma. J Hematol Oncol. 2022;15(1):141.
37. Sun Y, Ling C. Analysis of the long non-coding RNA LINC01614 in non-small cell lung cancer. Medicine (Baltimore). 2019;98(30):e16437.
38. Hou Y, Zhou M, Li Y, Tian T, Sun X, Chen M, et al. Risk SNP-mediated LINC01614 upregulation drives head and neck squamous cell carcinoma progression via PI3K/AKT signaling pathway. Mol Carcinog. 2022;61(8):797-811.
39. Chen LJ, Wu L, Wang W, Zhai LL, Xiang F, Li WB,
et al. Long non‑coding RNA 01614 hyperactivates WNT/β‑catenin signaling to promote pancreatic cancer progression by suppressing GSK‑3β. Int J Oncol. 2022;61(4):116.
40. Li L, Wei H, Zhang YW, Zhao S, Che G, Wang Y, et al. Differential expression of long non-coding RNAs as diagnostic markers for lung cancer and other malignant tumors. Aging (Albany NY). 2021;13(20):23842-23867.
| Files | ||
| Issue | Vol 18, No 2 (June 2024) | |
| Section | Original Articles | |
| DOI | https://doi.org/10.18502/jfrh.v18i2.15937 | |
| Keywords | ||
| Long Non-Coding RNA ( LncRNA) Breast Cancer Cancer Marker | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
How to Cite
1.
Behyari M, Behyari M. Expression of Intragenic LCAL4 Long Non-Coding RNAs as a Potential Diagnostic and Prognostic Marker in Female Breast Cancer. J Family Reprod Health. 2024;18(2):129-139.
